UNSPSC 51151608: Dicyclomine or dicycloverine

This classification denotes an antimuscarinic agent with the molecular formula C19H35NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 4KV4X8IF6V, chemically known as cyclohexanecarboxylic acid, 1-cyclohexyl-, 2-(diethylamino)ethyl ester but more generally known as dicyclomine, which bears US NIH Compound Identifier 3042. European Medicines Agency schedules Dicycloverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07103MIG.

UNSPSC 51151608 Dicyclomine or dicycloverine is a Commodity code that nominally covers a specific pharmaceutical active ingredient, but the recent state and local opportunities posted under this code show minimal relevance to the code's stated scope. The Seminole County, Florida opportunity (IFB60459723LAS, posted June 30, 2026, due July 26, 2026) solicits naloxone and drug deactivation systems for community health initiatives—a public-health opioid-response product line unrelated to dicyclomine. The Texas Health and Human Services Commission RFI (HHS0017013, posted April 3, 2026) seeks vendor capabilities for a direct-to-manufacturer pharmacy prescription program, which addresses pharmacy benefit management and contract-negotiation infrastructure rather than any specific pharmaceutical product. Neither opportunity targets the anticholinergic agent that the code name describes.

The issuing-body mix spans a county health department (Seminole County) and a state health commission (Texas HHS), indicating activity across both local and state health-care procurement functions. Geographically, the recent record shows activity in Florida and Texas. The code shows little decision-relevant recent activity aligned with its nominal pharmaceutical scope; the posted opportunities appear to be miscoded or represent peripheral pharmacy-system procurement rather than purchases of dicyclomine or dicycloverine as active ingredients. Business development professionals should treat this code as inactive for pharmaceutical supply purposes and verify actual commodity alignment before pursuing opportunities tagged under it.